The price of a drug for COVID-19 patients developed by India’s top defence research body has been fixed at ₹ 990 per sachet and it will be available commercially, according to the officials.
The oral drug was developed by the Institute of Nuclear Medicine and Allied Sciences, a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories.
Earlier this month, the Drugs Controller General of India (DGCI) approved the drug for emergency use as an adjunct therapy in moderate to severe Covid patients.
Commenting on DRDO’s 2-DG anti-Covid drug, Defence Minister Rajnath Singh on May 27 told the media, “I am happy that 10,000 sachets of the drug are coming to the market today”.
Karnataka Health Minister Dr K Sudhakar last week said that the 2DG drug developed by DRDO could be a game-changer in the fight against the COVID-19 virus.
Earlier, in a statement, the defence ministry said had that “the drug is expected to save precious lives due to the mechanism of its operation in the infected cells. This also reduces the hospital stay of COVID-19 patients”.
The drug comes in powder form in a sachet and is taken orally by dissolving it in water.
The price of DRDO’s 2-DG anti-Covid drug has been kept at ₹ 990 per sachet by Dr Reddy’s. Government hospitals, central and state governments would be provided the medicine at a discounted price, officials added.